Description
Erdafitinib
Each film-coated tablet contains: Erdafitinib … 3 mg
INDICATION
LuciErda is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has • Susceptible FGFR3 or FGFR2 genetic alterations and • Progressed during or following at least one line of prior platinum -containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.
DOSAGE AND USE
• Confirm the presence of FGFR genetic alterations in tumor specimens prior to initiation of treatment with LuciErda. • Recommended initial dosage: 8 mg orally once daily with a dose increase to 9 mg daily if criteria are met. • Swallow whole with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciErda during Pregnancy and Lactation.
Erdafitinib
Each film-coated tablet contains: Erdafitinib … 4 mg
INDICATION
LuciErda is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has • Susceptible FGFR3 or FGFR2 genetic alterations and • Progressed during or following at least one line of prior platinum -containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinumcontaining chemotherapy.
DOSAGE AND USE
• Confirm the presence of FGFR genetic alterations in tumor specimens prior to initiation of treatment with LuciErda. • Recommended initial dosage: 8 mg orally once daily with a dose increase to 9 mg daily if criteria are met. • Swallow whole with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciErda during Pregnancy and Lactation.
Erdafitinib
Each film-coated tablet contains: Erdafitinib … 5 mg
INDICATION
LuciErda is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has • Susceptible FGFR3 or FGFR2 genetic alterations and • Progressed during or following at least one line of prior platinum -containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinumcontaining chemotherapy.
DOSAGE AND USE
• Confirm the presence of FGFR genetic alterations in tumor specimens prior to initiation of treatment with LuciErda. • Recommended initial dosage: 8 mg orally once daily with a dose increase to 9 mg daily if criteria are met. • Swallow whole with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciErda during Pregnancy and Lactation.
Reviews
There are no reviews yet.